AI & DIGITAL ONCOLOGY
Is artificial intelligence a reliable partner for multidisciplinary tumour boards?
Real-world findings show moderate-to-high concordance between AI-generated and human experts decisions
AI in GI cancer care: From recognition to clinical value
Experts' discussions during the ESMO Gastrointestinal Cancers Congress 2026 explored how AI is moving beyond image recognition to support surgery, pathology and image-guided intervention.
From bottleneck to breakthrough: rethinking clinical data collection in the age of AI
Every day, clinicians generate thousands of reports containing critical data that will never be analysed. Not because it lacks value — but because extracting it remains a bottleneck.
NEW HORIZONS IN CANCER RESEARCH
New treatment modalities in gastrointestinal malignancies: broadening the therapeutic horizon
Rapid advances in molecular targeting, immunotherapy optimisation and novel drug classes are reshaping gastrointestinal oncology
Towards a chemotherapy-free future in breast cancer?
Recent studies support treatment optimisation for improving patients’ quality of life, but its implementation in clinical practice remains limited
The antibody–drug conjugate era in gynaecological cancers
Recent approvals are driving a shift toward biomarker-informed treatment strategies, rational combinations and personalised sequencing
OTHER NEWS
Novel data support the use of liquid biopsy to guide cetuximab rechallenge in metastatic colorectal cancer
Tumours with no ctDNA-identified pathogenic variants for anti-EGFR drug resistance genes appear to respond to continued cetuximab beyond disease progression
Early-phase studies point to efficacy of a nectin-4-targeting antibody-drug conjugate in cervical cancer
In advanced or metastatic disease, bulumtatug fuvedotin shows promising efficacy and manageable safety
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
OPINIONS
Early signs of progress in osteosarcoma research
Emanuela Palmerini
AI for early-phase clinical trials: from hype to proof of concept
Julien Vibert
Rethinking cancer vaccines through the tumour immunopeptidome
Juliane Walz
Reshaping the treatment landscape for GI cancers
Elizabeth Smyth
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa
OPINIONS
Early signs of progress in osteosarcoma research
Emanuela Palmerini
AI for early-phase clinical trials: from hype to proof of concept
Julien Vibert
Rethinking cancer vaccines through the tumour immunopeptidome
Juliane Walz
Reshaping the treatment landscape for GI cancers
Elizabeth Smyth
ctDNA is unlocking new clinical opportunities for liquid biopsy
Kosei Hasegawa